Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy

Subhojit Paul,Tanmoy Mukherjee,Kaushik Das

DOI: https://doi.org/10.3390/cancers16081568

2024-04-20

Cancers

Abstract:Blood coagulation and cancer are intrinsically connected, hypercoagulation-associated thrombotic complications are commonly observed in certain types of cancer, often leading to decreased survival in cancer patients. Apart from the common role in coagulation, coagulation proteases often trigger intracellular signaling in various cancers via the activation of a G protein-coupled receptor superfamily protease: protease-activated receptors (PARs). Although the role of PARs is well-established in the development and progression of certain types of cancer, their impact on cancer immune response is only just emerging. The present review highlights how coagulation protease-driven PAR signaling plays a key role in modulating innate and adaptive immune responses. This is followed by a detailed discussion on the contribution of coagulation protease-induced signaling in cancer immune evasion, thereby supporting the growth and development of certain tumors. A special section of the review demonstrates the role of coagulation proteases, thrombin, factor VIIa, and factor Xa in cancer immune evasion. Targeting coagulation protease-induced signaling might be a potential therapeutic strategy to boost the immune surveillance mechanism of a host fighting against cancer, thereby augmenting the clinical consequences of targeted immunotherapeutic regimens.

oncology

What problem does this paper attempt to address?

The paper primarily explores how blood coagulation-related proteases influence cancer development by promoting cancer immune evasion, and subsequently suggests the potential of these proteases as new targets for cancer immunotherapy.

Specifically, the paper aims to address the following core issues:

1. **Understanding the role of protease-activated receptors (PARs)**: What is the mechanism of action of PARs activated by blood coagulation-related proteases in cancer development? In particular, how do these proteases regulate immune responses in the tumor microenvironment through PARs signaling pathways?

2. **Revealing immune evasion mechanisms**: The paper discusses in detail how different types of coagulation proteases (such as thrombin, factor VIIa, factor Xa, etc.) promote cancer immune evasion by activating PARs, leading to tumor growth and development.

3. **Exploring therapeutic strategies**: Based on the above findings, the paper also explores the potential of targeting coagulation protease-induced signaling pathways as a therapeutic strategy to enhance the host's immune surveillance mechanisms against cancer and improve the effectiveness of immunotherapy.

In short, the main purpose of this review paper is to comprehensively summarize how coagulation protease-mediated PARs signaling affects cancer immune evasion and to propose the potential value of these findings for the development of new cancer immunotherapy methods.